Navigation Links
Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
Date:10/7/2008

AUSTIN, Texas, Oct. 7 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has been selected as one of only a few sites in the nation to participate in an FDA-approved clinical trial for a new device to treat persistent atrial fibrillation. TCAI, an international treatment, training and research center specializing in heart rhythm disorders, is a partnership between St. David's Medical Center and Texas Cardiovascular Consultants.

"This is just another example of how TCAI is leading the nation in pioneering new treatments for atrial fibrillation," Dr. Rodney Horton, electrophysiologist, Texas Cardiac Arrhythmia, said. "We are proud to take part in this study that has the potential to greatly enhance the future treatment of A Fib."

Heart arrhythmias are very common, affecting more than two million people nationwide. Atrial fibrillation, or A Fib, is the most common heart arrhythmia. A Fib is a rhythm disorder that affects the electrical system, or "wiring," of the heart muscle. It is often treated with cardiac ablation -- a procedure that allows physicians to deliver energy directly to the heart muscle at precise points that trigger the arrhythmia, creating a lesion that blocks the pathway for the abnormal heart rhythm. The new study involves second generation software (Gen II) that uses a catheter believed to result in the formation of a more effective lesion.

"In the Gen II study, we are evaluating a revolutionary radiofrequency ablation catheter," Dr. Horton said. "This device is able to monitor the temperature at its tip, giving electrophysiologists the ability to better control the delivery of energy through the catheter and generate a more effective lesion." In traditional cardiac ablation, room temperature saline is injected through the catheter prior to the delivery of energy. Because standard catheters do not measure the temperature at the catheter's tip, overheating may occur, resulting in th
'/>"/>

SOURCE The Texas Cardiac Arrhythmia Institute at St. David?sMedical Center
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
2. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
3. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
4. Personalized Medicine - The Genomic Revolution in Cardiac Care
5. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
6. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
9. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
10. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
11. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)... Successful Results from prior U.S., U.K. and Chin...Vital Therapies, Inc. (VTI), a development stage c...tient enrollment has begun for a randomized, contr...ill study the Extracorporeal Liver Assist Device (... Failure (ALF) under three protocols. The study is...
(Date:1/6/2009).... 6 In recent controlled studies c...mphis , scientists found that the patented ingredi...nd only proven ingredient to increase levels of ni...ood nitrate/nitrate (NOx) in human subjects. , ,...n increase in blood flow to the skeletal muscles. ...
(Date:1/6/2009)...n. 6 Sequella, Inc., a ...n diseases of epidemic potential, announced today ...ent of tuberculosis (TB), was the first drug appro...gram contract to Dynport Vaccine Company LLC and Q...he National Institute of Allergy and Infectious Di...
(Date:1/6/2009)...J., Jan. 6 Pacira Pharmaceuticals,...pany, announced today that enrollment,has been co...evaluate the,safety and efficacy of a single intr...ivacaine) for prolonged postoperative analgesia. ,...my and in total knee,arthroplasty (TKA) are expec...
Breaking Medicine Technology:ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3 C O R R E C T I O N from Source Resverlogix Corp 5055 1 C O R R E C T I O N from Source Resverlogix Corp 5055 2Cold Spring Harbor Protocols features classic approaches for analyzing chromosomes 3151 1ACC Observes National Drinking Water Week 18231 1ACC Observes National Drinking Water Week 18231 2Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 5052 1Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 5052 2Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 5052 3
(Date:1/8/2009)...sessment for heart risk may not be accurate in som...News) -- Two studies, from the United States and t... the long-established Framingham Risk Score in pre..., The Framingham score, based on findings of a de...allows doctors to assess risk on the basis of seve...
(Date:1/8/2009)...PRNewswire/ -- A study released this week showing ...rom multiple chronic diseases shines a much-needed...re system to one that focuses on primary and secon...cine, the leader in disease prevention. , , (...06/NETU129LOGO ) , , The study, conducted by ...
(Date:1/8/2009)... sitting on the surface of cancer cells are keys t...reating and stopping the spread of certain types o...e, breast, ovarian and lung, among others. Armed ...teway for Cancer Research, an Illinois-based phila...o, M.D., Ph.D., and her co-workers at the Moores C...
(Date:1/8/2009)...ude study could shape new treatments for secondary...re-USNewswire/ -- Scientists at St. Jude Children,...tive treatment for bacterial pneumonia following i...cin and azithromycin, which kill bacteria by inhib...than a standard first-line treatment with the "bet...
Breaking Medicine News(10 mins):Health News:Studies Challenge Framingham Risk Score 2Health News:Studies Challenge Framingham Risk Score 3Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3
...! New research released on Monday suggests that a ... healthy and prolongs life. These findings stem fr...e in nuns. "It's been known for years that patholo...ssion or hostility can lead to illness," said Davi...
... during clinical trials, may be the in thing in AI...e HIV from circulating blood, has been developed a... mark the beginning of the end of HIV’s vicious gr...rs at Aethlon Medical, a biotechnology firm in La ...
..., may opt for mastectomy over breast-conserving lu... gene mutation, researchers said California on Mon...sed by an inherited genetic susceptibility. The ma...utations or alterations in two genes, BRCA1 and BR...
... AIDS therapy, complimentary and alternative medic...e patients, according to a new study. Among 191 HI... complementary and alternative therapies, 67% said...t to control their HIV infection and 40% reported ...
Other Medicine News:
... modular external fixation system designed to acco...needs. Originally marketed in Europe under the Fix...y of clinical use in the global healthcare marketp...rov technique begun in Russia over 50 years ago, R...
...N AVIA tonometer is an easy-to-use, hand-held inst...trongly with Goldmann tonometry. TONO-PEN AVIA has...tronic measurement technology that enables operato... minimal training. TONO-PEN AVIA is powered by a l...
The QuickLink™ Delivery System is a cartridge based device designed to assemble brachytherapy seeds, spacers and SourceLink Connectors into seed trains of variable lengths and with variable seed
...ollection benefits from innovative research in mat...ectors such as the aerospace and automotive indust... and the footwear and textile industry. , ,This kn...Carrera sunglasses collection to create unique and...
Medicine Products: